2Laliberte J, Yee A, Xiong Y, et al. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood, 1998,91(8) :2896-2904.
3Blaheta RA, Lockel K, Wittig B, et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol, 1998,6(4) :251-259.
4Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibiton. J Am Soc Nephrol, 1998,9(12):2272-2282.
5Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm, 1997,54(3):285-294.
6Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet, 1998,34 (6): 429-455.
7Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol, 1999, 135(1) :54-56.
8Bredlich RO, Grundmann-Kollmann M, Behrens S, et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol, 1999,141 (5):934.
9Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol, 1999,40(6 Pt 1):957-960.
10Nousari HC, Griffin WA, Anhalt GJ, et al. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol, 1998,39(3) :497-498.
8Chaudhari U,Romano P,Mulcahy LD,et al.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomised trial[J].Lancet,2001,357:1842-1847.
9Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4[J].J Autoimmun,1998,11:53-62.
10Krueger JG,Walters IB,Miyazawa M,et al.Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis[J].J Am Acad Dermatol,2000,43:448-458.
